Survey of pharmacists' and physicians' perceptions of therapeutic interchange
- PMID: 15943216
- DOI: 10.1007/BF02850178
Survey of pharmacists' and physicians' perceptions of therapeutic interchange
Abstract
Therapeutic interchange has long been an integral part of drug formulary management, but physicians' and pharmacists' attitudes toward such programs are relatively unknown. This survey was undertaken to determine pharmacists' attitudes, physicians' potential response to a hypothetical interchange, and how well pharmacists predicted physicians' responses. A survey that described a drug interchange program and several potential responses to the proposed switch was provided to 300 staff physicians at a 512-bed community facility in southwest Florida; the survey was also mailed to pharmacy directors or clinical pharmacy coordinators at 42 southwest Florida hospitals. Responses were obtained from 98 physicians and 95 pharmacists. Most physicians would not cooperate with an interchange if they were not familiar with the proposed drug; 16% would continue to prescribe the original drug, knowing that the new agent would be provided; and 58% would switch to another agent with which they had clinical experience. Only 26% of physicians would follow the interchange program. In contrast, 48% of pharmacists believed that physicians would continue to order the original therapy, 32% believed that physicians would order the new agent, and only 20% believed that physicians would switch to an alternative drug (P<.005 vs physician responses). Clearly, pharmacists' expectations of physicians' response to a therapeutic interchange differ significantly from the physicians' expected behavior. This difference has potentially important implications for actual versus projected cost savings of therapeutic interchange.
Similar articles
-
Comprehensive therapeutic interchange program in a community hospital.Am J Hosp Pharm. 1991 Jul;48(7):1471-7. Am J Hosp Pharm. 1991. PMID: 1882876
-
Formulary management as a tool to improve medication use and gain physician support.Am J Health Syst Pharm. 2007 Mar 1;64(5):464-6. doi: 10.2146/ajhp060332. Am J Health Syst Pharm. 2007. PMID: 17322158 No abstract available.
-
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.Am J Health Syst Pharm. 2002 Mar 15;59(6):529-33. doi: 10.1093/ajhp/59.6.529. Am J Health Syst Pharm. 2002. PMID: 11908245
-
Pharmacists' perceptions of the effectiveness of antimicrobial control programs.Am J Health Syst Pharm. 2006 Dec 15;63(24):2504-8. doi: 10.2146/ajhp060131. Am J Health Syst Pharm. 2006. PMID: 17158699
-
Tackling the challenges of nanomedicines: are we ready?Am J Health Syst Pharm. 2021 Jun 7;78(12):1047-1056. doi: 10.1093/ajhp/zxab048. Am J Health Syst Pharm. 2021. PMID: 33599767 Free PMC article. Review.
Cited by
-
Impact of non-formulary drugs on pharmacological prescription in hospitalised patients.Eur J Hosp Pharm. 2021 Nov;28(Suppl 2):e92-e96. doi: 10.1136/ejhpharm-2020-002204. Epub 2020 Oct 8. Eur J Hosp Pharm. 2021. PMID: 33033109 Free PMC article.
-
Systematic literature review of the methodology for developing pharmacotherapeutic interchange guidelines and their implementation in hospitals and ambulatory care settings.Eur J Clin Pharmacol. 2019 Feb;75(2):157-170. doi: 10.1007/s00228-018-2573-7. Epub 2018 Oct 19. Eur J Clin Pharmacol. 2019. PMID: 30341498
-
ePrescribing: Reducing Costs through In-Class Therapeutic Interchange.Appl Clin Inform. 2016 Dec 14;7(4):1168-1181. doi: 10.4338/ACI-2016-09-RA-0160. Appl Clin Inform. 2016. PMID: 27966005 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources